GlassScriptPhysician profile
Nancy S Reau
NPI 1164585683
$357,164.12
in general payments reported to CMS, 2019-2025
45 companies · $49K in 2025
The $49K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $39K · 2021: $57K · 2022: $18K · 2023: $79K · 2024: $48K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $114K · Travel and Lodging: $45K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Food and Beverage: $5,050 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $113,757.98 |
| Travel and Lodging | $44,639.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,675.00 |
| Food and Beverage | $5,049.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $179,955.47 | 2019-2025 | Vemlidy, Epclusa |
| Abbvie INC. | $52,962.49 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50,052.60 | 2019-2025 | Xifaxan, Plenvu |
| Novo Nordisk INC | $26,125.71 | 2022-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $18,633.06 | 2019-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $8,285.00 | 2020-2025 | Terlivaz |
| Abbott Laboratories | $4,778.69 | 2019-2024 | Architect |
| E.R. Squibb & Sons, L.L.C. | $4,326.00 | 2019 | |
| Glaxosmithkline, LLC. | $4,300.00 | 2023-2025 | |
| Echosens North America, INC. | $1,515.00 | 2021 | |
| Mindray Ds USA, INC. | $1,500.00 | 2023 | Te7 Max |
| Takeda Pharmaceuticals U.S.A., INC. | $1,240.99 | 2021-2025 | Gattex, Entyvio, Livtencity |
| Bausch Health US, LLC | $800.00 | 2025 | |
| Madrigal Pharmaceuticals | $549.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Cook Medical LLC | $255.01 | 2022-2023 | Hemospray |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $248.88 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Celgene Corporation | $210.01 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $178.30 | 2022-2024 | Axios |
| Merck Sharp & Dohme LLC | $170.64 | 2020-2023 | Zinplava, Dificid |
| Biocompatibles, INC. | $146.92 | 2019 | |
| Janssen Scientific Affairs, LLC | $136.36 | 2022 | |
| Qol Medical, LLC | $119.14 | 2022-2025 | Sucraid |
| Ethicon US, LLC | $106.13 | 2019 | |
| Genentech, INC. | $87.64 | 2022 | |
| Mirum Pharmaceuticals, INC. | $84.77 | 2024-2025 | Livmarli |
| Ardelyx, INC. | $83.24 | 2022-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $36.01 | 2024-2025 | Vowst |
| Shionogi INC | $34.37 | 2019 | |
| Vivus LLC | $32.33 | 2020-2021 | |
| Medtronic, INC. | $32.13 | 2022 | |
| Ferring Pharmaceuticals INC. | $31.52 | 2020-2023 | Rebyota |
| Sequana Medical US INC. | $24.25 | 2025 | Alfapump System |
| Phathom Pharmaceuticals, INC. | $21.74 | 2024 | Voquezna |
| W. L. Gore & Associates, INC. | $15.87 | 2020 | |
| Organon LLC | $15.69 | 2023 | Hadlima |
| Astrazeneca Pharmaceuticals LP | $15.15 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.12 | 2021 | |
| Albireo Pharma, INC. | $13.49 | 2024 | |
| Dova Pharmaceuticals | $13.02 | 2019 | |
| Lilly USA, LLC | $12.74 | 2023 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Reau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.